Wilson's Disease Treatment Market
Wilson’s disease is a genetic disorder caused by the loss of function of the ATP7B copper-binding protein that leads to impaired copper transport and excretion, which results in accumulation of free copper in the bloodstream that results in damage of liver, brain, and other organs. As Wilson’s disease is hard to differentiate from other serious hepatic or neurologic condition that result in less number of patient to be diagnosed than the actual prevalence of Wilson’s disease. Wilson’s disease is characterized by the degree of accumulation of free copper in liver and the brain. Whereas, the patients that suffer from Wilson’s disease can either be asymptomatic or can have one or more clinical symptoms which can vary in type and its severity that include liver disease, neurologic manifestations and psychiatric disturbances. The symptoms for Wilson’s disease may include abdominal pain, lack of appetite, fatigue, jaundice, problems with speech, swallowing or physical coordination and uncontrolled movements or muscle stiffness.
Wilson disease is suspected in the individual of age 3 - 60 years, whereas the chance of child inheriting autosomal recessive mutation from both the parent by gene mutation is 25% or one in four ratio.
The global Wilson's disease treatment market was valued at US$ 392.0 million in 2016 and is expected to witness a robust CAGR of 6.0% during the forecast period (2017-2025).
Wilson's Disease Treatment Market Value (US$ Million), 2017
Rapid advancements in technology allowing for early detection driving growth of the Wilson’s disease treatment market
North America accounts for the largest share in the global Wilson’s disease treatment market, followed by Europe. This is mainly attributed due to rapid growth in aging population in these regions. Asia Pacific is expected to emerge as a fast growing market for Wilson’s disease over the forecast period. Increasing population in China and India position these as highly lucrative markets for Wilson’s disease treatment. Increase in health expenditure on healthcare further fuels growth of Wilson’s disease treatment market in the region. The market is expected to show high growth rate in Asia Pacific region over the forecast period as Asia consist of 60% of the world’s current population and as Wilson’s disease is a hereditary disease the chance of expansion of this disease is more in Asia Pacific region. According to National Institute on Aging in 2010 it was estimated that 524 million people were aged 65 or older that is 8% of the world's population and by 2050, which is expected to nearly triple the number to 1.5 billion, representing 16% of the world's population. This above mentioned statistics is expected favor the growth of Wilson’s disease treatment market.
Increase in awareness regarding Wilson’s disease is expected to fuel the Wilson’s disease treatment market in near future
There are various organization and association working to create the awareness regarding Wilson’s disease for example, Wilson’s disease association is a volunteer organization striving to promote the well-being of the patients with Wilson’s disease where they offer the latest information about disease and its symptoms and treatment. Moreover Wilson’s disease association supports research and clinical investigation for Wilson’s disease.
Furthermore, manufacturers also significantly supports the Wilson’s disease awareness programs for example, in 2016, Valeant pharmaceutical announced company’s commitment to improve the lives of Wilson’s disease patients around the world, whereas Valeant has agreed to provide US$ 100,000 to fund enhanced patient awareness and research into the Wilson’s disease.
Some major players operating in the Wilson’s disease treatment market are Valeant Pharmaceuticals International, Inc., Noblepharma Co., Ltd., Wilson Therapeutics AB, Kadmon Holdings, Inc., Merck & Co., Inc., VHB Life Science Ltd., Teva Pharmaceuticals USA, Inc. and Tsumura & Co.
Few growth restraining factors are due to diagnosing and less awareness regarding the symptoms of the Wilson’s disease among the people hampers growth of the Wilson’s disease treatment market.
Wilson’s disease, also known as hepatolenticular degeneration or progressive lenticular degeneration, is a rare genetic disorder caused by copper poisoning in the body. In a healthy body, the liver filters the excess copper and releases it through urine. The liver of a person suffering from Wilson’s disease cannot perform this function. Wilson’s disease is diagnosed by blood tests where abnormalities in liver enzymes, copper levels in the blood, lower levels of ceruloplasmin, a protein that carries copper through the blood, a mutated gene or low blood sugar. Treatment include oral drug containing zinc, d-penicillamine, Tetrathiomolybdate and trientine or syprine.
Increasing awareness regarding Wilson’s disease and its symptoms is expected to fuel the market of Wilson’s disease treatment market in the near future. Moreover, growing population all over the world is expected to boost the growth of Wilson’s disease market.
Rising incidence of Wilson’s disease is due to increase in the population worldwide as Wilson’s disease is a rare genetic disorder which, is expected to favor the demand for Wilson’s disease treatment market around the globe.
According to the European Association for the study of liver (EASL) in 2011 published that Wilson’s disease is a genetic disorder that is found worldwide and is recognized to be more common than previous, with a gene frequency of 1 in 90 -150 and an incidence that is 1 in 30,000 and more than 500 distinct mutations are described in the Wilson’s gene from which 380 have a confirmed role in the pathogenesis of the disease. Whereas, European Association also stated in year 2011 that Wilson’s disease accounts for 6 - 12% of all patient with acute liver failure who are referred for emergency transplantation.
This report segments the Wilson’s disease treatment market on basis of treatment type and the Distribution channel. On basis of treatment type, market is categorized into Medications and others. Among these medications segment dominates the Wilson’s disease treatment market throughout the forecast period. Further medication segment is sub-categorized into D-Penicillamine, Trientine, Zinc and Tetrathiomolybdate where D-penicillamine dominates the medication segment. On the basis of the distribution channel Wilson’s disease treatment market is divided into Hospitals pharmacies, Government distribution channel, retail and e-pharmacies among which hospital pharmacies dominates the market throughout the forecast period. Last segment of the market is by geography which includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Among all regions, North America contributes major market share supported by increased incidence rate of Wilson’s disease and growing inclination of the populace towards its treatment.
Key features of the study:
This report provides in-depth analysis of the Wilson’s disease treatment market and provides market size (US$ Mn) and Cumulative Annual Growth Rate (CAGR) (%) for the forecast period (2017–2025)
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, new product launches or approval, pipeline products, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global Wilson’s disease treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions with respect to their future product launch, market expansion, and marketing tactics
The global Wilson’s disease treatment market report to various stakeholders in this industry, including investors, product developers, distributors, healthcare companies, research institutes, medical device companies, new entrants, and financial analysts
Stakeholders would greatly benefit in decision making through the various strategy matrices used in analyzing the Wilson’s disease treatment market
Table of Contents
*Browse 90 market data tables and 40 figures on "Wilson’s Disease Treatment Market - Global forecast to 2025”.
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.